Cancer genetics

Week of 10 November 2026

8 articles

Geno'X Veille — genox-veille.fr

Key takeaways this week

►BARD1 — Across 445 families, increased pancreatic and prostate cancer risks (RR 3.02; 36.11% absolute risk to age 85) in addition to breast cancer.
►BRCA1, BRCA2, ATM, PALB2 — Among 2,085 carriers under pancreatic surveillance (PRECEDE), imaging findings are common (54%), concerning in 9.1% and mostly stable on short-term follow-up.
►BAP1 — Ascertainment-corrected cumulative risks at 80 years across 26 families: 49.4% for renal cell carcinoma, 58.6% for breast cancer.
►RET — The p.C634R variant increases pheochromocytoma penetrance (67% vs 37%) without worsening medullary thyroid carcinoma.
►Childhood cancer — Predisposition syndrome in 6.9% of 888 children, recognised after the cancer in 72.1% of cases; Jongmans criteria 98.4% sensitive at the one-criterion threshold.

Category:

Filters··Min. score

8 articles of 8

Sort

Cancer Risks Associated With Germline BARD1 Pathogenic/Likely Pathogenic Variants: A Multicenter Study of 445 Families

Hereditary cancer predisposition (BARD1)

Breast cancerPenetrance updatePhenotypic expansion

JCO Precis Oncol 2026· NovRead

BRCA1, BRCA2, ATM, PALB2

Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study

Pancreatic cancer surveillance in BRCA1, BRCA2, ATM or PALB2 carriers

JCO Precis Oncol 2026· NovRead

Risk estimates in BAP1 tumor predisposition syndrome using the Genotype-Restricted Likelihood (GRL) method

BAP1 tumour predisposition syndrome

Germline predispositionPenetrance update

Genet Med 2026· NovRead

Germline predisposition

Prevalence, clinical spectrum and predictors of cancer predisposition syndromes in childhood cancer

Childhood cancer predisposition syndromes

Germline predisposition

Eur J Pediatr 2026· NovRead

Clinical features and outcomes of MEN2A with RET codon 634 pathogenic variants

Multiple endocrine neoplasia type 2A (RET codon 634)

Germline predispositionPenetrance update

J Endocr Soc 2026· OctRead

Germline predisposition

Germ line Mutation Incidence in Patients with Prostate Cancer and Additional Cancers

Prostate cancer: germline predisposition and prior cancer history

Germline predisposition

Eur Urol Focus 2026· NovRead

Polygenic risk score

Improving Consistency in Colorectal Cancer Genetic Risk Assessment and Return of Results Through an Integrated Polygenic Risk Score

Colorectal cancer: polygenic risk score

Polygenic risk score

medRxiv 2026· NovRead

Autosomal dominantPubMed

Global population-based prevalence of genetic carriers of CDH1-associated hereditary diffuse gastric cancer

Hereditary diffuse gastric cancer (CDH1)

Gastric Cancer 2026· NovRead

References and sources

BARD1 — Hereditary cancer predisposition (BARD1). JCO Precis Oncol 2026. PMID 43002722. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/43002722/
BRCA1, BRCA2, ATM, PALB2 — Pancreatic cancer surveillance in BRCA1, BRCA2, ATM or PALB2 carriers. JCO Precis Oncol 2026. PMID 42976359. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42976359/
BAP1 — BAP1 tumour predisposition syndrome. Genet Med 2026. PMID 42985853. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42985853/
Childhood cancer predisposition syndromes. Eur J Pediatr 2026. PMID 42993354. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42993354/
RET — Multiple endocrine neoplasia type 2A (RET codon 634). J Endocr Soc 2026. PMID 42978830. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42978830/
Prostate cancer: germline predisposition and prior cancer history. Eur Urol Focus 2026. PMID 42982618. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42982618/
Colorectal cancer: polygenic risk score. medRxiv 2026. doi:10.64898/2026.11.06.26367439. Score 6/10. https://www.medrxiv.org/content/10.64898/2026.11.06.26367439v1
CDH1 — Hereditary diffuse gastric cancer (CDH1). Gastric Cancer 2026. PMID 43002353. Score 4/10. https://pubmed.ncbi.nlm.nih.gov/43002353/

3 November 2026